Shanghai Escugen Biotechnology Co., Ltd. was established in 2017 in Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, focusing on the R&D of ADC drugs. The founding team has decades of industrial R&D experience in top-tier biopharmaceutical companies of both international and domestic. The expertise of the team covers the whole multi-functional drug development processes, including antibody engineering, bio-conjugation technology, CMC, and clinical development.
The EZWi-Fit® linker-payload technology is an ADC technical platform invented by Escugen. Its global intellectual property is wholly owned by Escugen. The ADCs based on EZWi-Fit® have significant competition advantages comparing with the GGFG-Dxd ADCs with respect to efficacy and safety. The EZWi-Fit® based ADCs have great potential to meet the unmet medical needs.
EZWi-Fit® Technology Platform employs stable-cleavable linkers and a Topoisomerase I (TopI) inhibitor payload. ADCs generated using this platform demonstrate significantly higher in vivo activity against multiple therapeutic targets compared to ADCs with other TopI inhibitors as payloads in various preclinical models.
ADC Drugs
mAb Drugs
